triple agonist retatrutide Retatrutide, an investigational hormone receptor that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and Retatrutide Obesity Triple Agonist Targeting

Retatrutide is currently in Phase 3 clinical development under the TRIUMPH program, which includes obesity, type 2 diabetes, osteoarthritis-related weight outcomes, and MASLD endpoints

However, when using semaglutide for weight loss, some people may experience a reduction in overall body weight, which can include a combination of fat and muscle loss

, ,

Both groups had a reduced-calorie diet for 3 months

The most common side effects reported in retatrutide trials are nausea, vomiting, diarrhea, and constipation

Its multifaceted approach, targeting GLP-1, GIP, and glucagon receptors, has demonstrated significant weight reduction, improved glycemic control, and cardiovascular benefits